An observational study in Head Neck Cancer and Oral Cancer, sponsored by Banaras Hindu University. Recruiting at 1 site in India. Open to participants aged 18 Years to 100 Years. Per ClinicalTrials.gov, last updated 2024-08-13.
Sponsored by Banaras Hindu University · Observational
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 23 studies in Mouth Neoplasms with a site in India — 8 open to participants now, 9 under way, 1 of them phase 3. Mouth Neoplasms · India.
Among the 23 studies in Mouth Neoplasms with a site in India, this one is one of 3 that started in 2017, is the only observational one, and was the 12th registered.
447 studies on the registry are indexed under Mouth Neoplasms; 131 are open to participants now.
Browse Mouth Neoplasms studies →8 of the 23 studies in Mouth Neoplasms with a site in India are open now. Recruiting first, the newest first:
Kolhapur Cancer Centre - Cancer Centers of America · Sites in India
Ages 21–75
Kolhapur Cancer Centre - Cancer Centers of America · Sites in India
Ages 21–75
Tata Memorial Hospital · Sites in India
Ages 18–80
All India Institute of Medical Sciences, Jodhpur · Sites in India
Ages 18–75
Dr.Pankaj Chaturvedi · Sites in India
Ages 18–100
A study can be open while its sites in India have not opened yet or have stopped. Only those recruiting at a site in India →
Of the 97 Mouth Neoplasms studies recruiting now, 58 (60%) set no upper age limit and 23 (24%) stop at 75 or younger; 5 take children under 18; 14 take healthy volunteers.
This study: 18 Years to 100 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
23 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 3 · Phase 2 4 · Phase 3 6
First in 2004; this study’s year is marked. 3 started in 2017.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 200 is above the median of 100 across 114 observational studies indexed under Mouth Neoplasms.
Median enrollment 140 across the 22 interventional studies, 200 across the 1 observational. Of the 11 that completed or were terminated, 1 (9%) have results posted.
This tab as a report to print or save as PDF → With an account.
1 of 23 have an industry lead sponsor. The 10 most frequent:
Banaras Hindu University is the lead sponsor of 21 studies on the registry; 2 are open to participants now.
Banaras Hindu University has 4 studies filed under Mouth Neoplasms — fewer than ten, so there is no comparison to draw.
3 of the studies in Mouth Neoplasms with a site in India that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06737822Phase 3All India Institute of Medical Sciences, JodhpurUpfront Surgery Vs Induction Chemotherapy Followed By Surgery In Oral Cancers: | 2027-10 |
| NCT04809324Dr.Pankaj ChaturvediGross Examinations Versus Frozen Section for Assessment of Surgical Margins in Oral Cancers | 2026-12 |
| NCT05969314Tata Memorial HospitalTo Check Safety of Ayurvedic Oral Cannabis in Breast and Head and Neck Cancer | 2026-12-30 |
Add all 3 to your calendar (.ics) → With an account.
Among the 23 studies in Mouth Neoplasms with a site in India, from their registry updates:
This tab as a report to print or save as PDF → With an account.
Based on the recently identified mutations in HNSCCs, the major pathologic pathways implicated in the tumorigenesis of HNSCC include dysregulation of four processes:
Alterations of these genes are most frequently seen in alcohol and tobacco-related HNSCC. However their role in prognostication and selection of therapeutics is not known
Sample size:
Patients with squamous cell carcinoma of oral cavity fulfilling the inclusion and exclusion criteria and willing to participate will be included in this study.
Method:
Comprehensive history and physical examination of the patients will be carried out and all the details will be recorded in the preset proforma. All routine investigations as indicated including a biopsy to establish a diagnosis and CT of the head and neck to measure the tumor dimensions and stage the disease before initiation of treatment will be recorded. The paraffin embedded tissue will be studied for expression of various genetic mutations using NGS platform. Brush cytology will be collected in liquid medium for HPV typing using PCR.
The Ion AmpliSeq™ Cancer Hotspot Panel v3 will be used to detect hotspot regions of 161 oncogenes and tumor suppressor genes This research panel, with improved primer design, contains 4,648 total 4 pools (DNA pool 1: 1,891 amplicons. DNA pool 2: 1,890 amplicons. RNA pool 1: 447 amplicons. RNA pool 2: 420 amplicons.), enabling researchers to sequence challenging samples of formalin-fixed, paraffin-embedded (FFPE) tissue. Copy Number Variants (CNVs), Gene Fusions, Insertions-Deletions (indels), Single Nucleotide Polymorphisms (SNPs), Somatic Variants are identified.
HPV DNA PCR METHODOLOGY
DNA will be isolated by using QIAamp DNA mini kit (Qiagen, Hilden, Germany). The presence of HPV will be detected by using the digene® HC2 HPV DNA Test- The digene HC2 HPV DNA Test uses Hybrid Capture 2 technology to detect high-risk and low-risk HPV genotypes. It uses in vitro microplate assay based on signal-amplified nucleic acid hybridization that uses chemiluminescence for the qualitative detection of 18 types of human papillomavirus (HPV) (13 high risk and 5 low risk) DNA in cervical specimens. The test uses an RNA probe cocktail that detects 13 high-risk HPV types (16/18/31/33/35/39/45/51/52/56/58/59/68) and 5 low-risk types (6/11/42/43/44).
447 studies on the registry are indexed under Mouth Neoplasms; 131 are open to participants now.
This study's planned enrollment of 200 is above the median of 100 across 114 observational studies indexed under Mouth Neoplasms.
Browse Mouth Neoplasms studies →Banaras Hindu University is the lead sponsor of 21 studies on the registry; 2 are open to participants now.
Compared within Mouth Neoplasms, this study's primary condition as ClinicalTrials.gg classifies it; the registry's first condition term is Head and Neck Neoplasms. The counts are of registry records indexed under each term, refreshed daily. How we classify →
Histologically proven cases of Head and neck cancer undergoing treatment will be included, Next generation sequencing will be done and cohort will be followed up for 10 years
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).
Your pathology report is the document that shows this.
Histologically or cytologically confirmed
The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).
Your pathology report is the document that shows this.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Histologically diagnosed cases of head and neck cancer
Other: Next generation Sequencing
Next generation sequencing for 161 genes
Over all survival
Survival time from the diagnosis to death
Time frame: 10 years
Relapse free survival
survival time from diagnosis to recurrence or metastasis
Time frame: 10 years
Progression free survival
The time from the diagnosis to progression of disease
Time frame: 5 years
Plan to share: Yes — On request
Supporting information: Study protocol, Statistical analysis plan, Informed consent form, Clinical study report
Time frame: 6 months
Access criteria: On request
Started Apr 2017 (actual). Primary completion is estimated for Dec 2027, 128 months after the start.
Of 44 non-industry observational studies under Mouth Neoplasms, half reached primary completion within 47 months of starting (the median), counting those still running; a quarter within 23 and three quarters within 216. This study's planned 128 months is above that.
Counting every sponsor, half of 48 studies reached it within 47 months; a quarter within 23 and three quarters within 216.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Banaras Hindu University